21:38 , Aug 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Melding bispecifics and CAR T cells to treat glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer An anti-EGFRvIII CAR T cell engineered to secrete an anti-CD3, anti-EGFR bispecific antibody could treat glioblastoma. In a mouse model of EGFRvIII-positive or EGFRvIII-negative glioblastoma, the engineered cells decreased...
20:13 , Aug 15, 2019 |  BC Innovations  |  Translation in Brief

Marrying CARs and bispecifics for solid tumors

Companies are split on whether CAR T cells or bispecifics will be most efficacious in solid tumors, but one group thinks the best bet is to combine the approaches. A Harvard Medical School team unveiled...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
15:19 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
19:45 , Sep 10, 2018 |  BC Extra  |  Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
18:23 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; brain cancer; solid tumors Mouse studies suggest liposomal nanoparticles loaded with immunomodulatory agents could enhance the efficacy of CAR T therapies to treat solid cancers. The liposomal nanoparticles are coated with an...
21:06 , May 16, 2018 |  BC Extra  |  Preclinical News

Nanoparticle pretreatment could boost solid tumor CAR T therapy

Research from the University of Washington and the Fred Hutchinson Cancer Research Center suggests preconditioning cancer patients with immunomodulatory nanoparticles could increase the efficacy of CAR T therapies to treat solid tumors. The main hypothesis...
08:00 , Feb 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Glioblastoma Epidermal growth factor receptor variant III (EGFRvIII); prominin 1 (PROM1; CD133) Studies in patient samples and mice suggest a bispecific...
07:00 , Jun 14, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Inducible nitric oxide synthase 2 (NOS2; iNOS); epidermal growth factor receptor variant III (EGFRvIII) In vitro and mouse studies suggest iNOS inhibitors could...